Milind Desai MD MBA
@DesaiMilindY
Followers
2K
Following
749
Media
68
Statuses
650
Vice Chair, Dir Hcm Ctr, Med Dir Aortic Ctr, HVTI, DirClinOps , CVM, Haslam Chair, Prof of Med, Cleveland Clinic. Visiting Prof, Univ Oxford, UK, views mine
Cleveland, OH
Joined February 2018
🫀Happy to share our work on the Role of Treadmill Stress Echo in over 1200 Asymptomatic HCM Patients. With TSE, 22% had latent LVOTO and 37% patients achieved <85% AGP-METs, a/w worse long term outcomes. @DesaiMilindY @CleClinicHVTI @JACCJournals 🔗 https://t.co/4gceutnBT0
0
15
70
Mavacamten results in sustained favorable long-term cardiac remodeling in symptomatic obstructive hypertrophic cardiomyopathy - 128-week outcomes from the VALOR-HCM trial. https://t.co/MUHm082SMJ
#cvHCM #JACCIMG #oHCM #cvImaging @DesaiMilindY @jeffreygeske
0
8
36
🫀Happy to share our work on sex-based differences of outcomes in over 14,000 patients with ascending aortic dilation. Despite fewer comorbidities and higher surgical rates, women had worse long‐term survival. @DesaiMilindY @CleClinicHVTI @CCF_IMCHIEFS
https://t.co/s1kyhPoxwK
ahajournals.org
7
10
45
Full article: CYP450 activity, drug interactions and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors @tikuowens @mmartinezheart #michele michels
tandfonline.com
Several sarcomeric gene abnormalities associated with left ventricular thickening, hypercontractility, and high left ventricular ejection fraction define hypertrophic cardiomyopathy (HCM). Standard...
0
3
8
Thanks to all who joined us today, for an engaging symposium in Columbus, OH! Looking forward to Advances in Cardiovascular Care 2026🫀
Join us next week for Advancing Cardiovascular Care 2025 in Columbus, OH! @ClevelandClinic will review advances in the prevention, diagnosis & management of CVD — including new technologies & therapeutic options available to clinicians. Link to register: https://t.co/iZTGhDyUjd
0
7
28
🫀Happy to present our work on long-term outcomes in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy at #AHA25 Always grateful for the support of my mentor @DesaiMilindY and the whole team! @ClevelandClinic @CleClinicHVTI @CCF_IMCHIEFS
13
10
72
Shoutout to @desaimilindy & @tikuowens for an insightful and engaging discussion at #AHA25! Real-world strategies for better patient care. 📺 Replay available here: https://t.co/MsJM1gG8Gy Thanks to @bmsnews for supporting this #CME activity. #MedEd
0
3
8
Incredibly powerful #AHA25 session on breakthrough advances in #HCM — deep phenotyping for SCD risk to reverse remodeling with CMIs, emerging gene therapies, and—most importantly—the voice of the patient. 👏👏♥️@DesaiMilindY @tikuowens
2
4
18
SIMULTANEOUS PUBLICATION AT #AHA25 🔥 First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy Explore initial safety, pharmacodynamic, & imaging results from MyPEAK-1 https://t.co/2Oyn0jvSXu
#CVD #CardiovascularResearch
0
10
19
Today, @DesaiMilindY shared new interim clinical data on MyPEAK™-1 Phase 1b/2 clinical trial for TN-201 at #AHA25. Missed it? Tune into our webcast on Monday (11/10) at 8 am EST. Details in our press release: https://t.co/2naQurPGvL
#GeneTherapy #HeartDisease
2
3
15
Traditional #HCM treatments often fall short—but cardiac myosin inhibitors are changing the game! 🚀 Join @PeerView & the experts @DesaiMilindY & @tikuowens tomorrow (11/8, 5:30 PM CST) at #AHA25 for expert guidance. Save your spot‼️ 👉 https://t.co/cmv3RESeUY
#cardiology #MedEd
peerview.com
MDADI
0
4
5
We are looking forward to our late breaking clinical and preclinical presentations at #AHA25 Scientific Sessions presented by @DesaiMilindY and Kathy Ivey, Ph.D.! Read the press release for further details here: https://t.co/FtQxnZDZrW
1
3
10
🫀 Pathophysiology & Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy @JACCJournals #CardioX #Cardiology #Cardioed
2
28
83
At end of trial, Mava improved gradients, volumes, LA strain, diastolic dysfunction and global hypertrophy. Final results of the VALOR Trial. Was a pleasure to be on the steering committee with @DesaiMilindY @tikuowens
pubmed.ncbi.nlm.nih.gov
In the VALOR-HCM trial, treatment with mavacamten resulted in sustained favorable cardiac remodeling, including improvement in LVOT gradients, cardiac volumes, cardiac hypertrophy, diastolic functi...
2
5
18
Type 2 MI now accounts for over 25% of all MIs, with lower short-term but higher long-term mortality than type 1 MI @DesaiMilindY
@JJheart_doc @tavrkapadia @UTSWheart @ziadak @amgadmentias @LannyHallMD @NeilKeshvani @ambarish4786 #AHAJournals
https://t.co/ZdERijQwBM
0
6
18
It’s not too late to register for #Cardiovascular Update 2025🫀 Join @ClevelandClinic & @ABCardio1 Oct 16 & 17 to learn about the latest science & best-practices to improve the prevention, management & outcomes for individuals with — or at risk for CVD. https://t.co/Ko1gBQLh0J
0
4
14
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Car...
4
3
14
Real‐World Observations in Obstructive Hypertrophic Cardiomyopathy Patients Treated with Mavacamten: Evidence of Favorable Disease Modification | Journal of the American Heart Association @CleClinicHVTI data on 244 #oHCM pts @ esc2025 w simpub
ahajournals.org
2
11
41
Happy to share our work on the largest natural history study for asymptomatic HCM patients to date @CleClinicHVTI . Presented #ESCCongress2025 and simultaneously published in @JACCJournals Grateful for my mentor @DesaiMilindY and our incredible team! @CCF_IMCHIEFS
Characteristics and Long-Term Outcomes of Asymptomatic Patients With H... https://t.co/3yVmFKMOy9 Largest natural history study to date in 3,393 NYHA 1 HCM patients from @CleClinicHVTI. Presented at #ESCCongress2025 and simultaneously published in @JACCJournals
12
10
61